• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.

作者信息

Tré-Hardy Marie, Cupaiolo Roberto, Wilmet Alain, Beukinga Ingrid, Blairon Laurent

机构信息

Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium; Faculty of Medicine, Université libre de bruxelles, Brussels, Belgium; Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, Belgium.

Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, Brussels 1050, Belgium.

出版信息

J Infect. 2021 Sep;83(3):381-412. doi: 10.1016/j.jinf.2021.06.017. Epub 2021 Jun 20.

DOI:10.1016/j.jinf.2021.06.017
PMID:34161817
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8214908/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7485/8214908/751d8c43ac55/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7485/8214908/751d8c43ac55/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7485/8214908/751d8c43ac55/gr1_lrg.jpg

相似文献

1
Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.未感染过新冠病毒的疫苗接种者体内抗体水平下降：对医护人员中mRNA-1273疫苗进行的持续免疫原性和疗效监测的三个月中期分析结果
J Infect. 2021 Sep;83(3):381-412. doi: 10.1016/j.jinf.2021.06.017. Epub 2021 Jun 20.
2
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary.mRNA-1273 COVID 疫苗在医护人员 6 个月监测后的免疫原性；需要接种第三剂。
J Infect. 2021 Nov;83(5):559-564. doi: 10.1016/j.jinf.2021.08.031. Epub 2021 Aug 23.
3
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.一项评估 COVID-19 疫苗 mRNA-1273 在健康日本成年人中的 1/2 期随机、安慰剂对照研究：中期报告。
Vaccine. 2022 Mar 18;40(13):2044-2052. doi: 10.1016/j.vaccine.2022.02.030. Epub 2022 Feb 8.
4
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
5
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.移植受者中第三剂mRNA-1273疫苗的随机试验。
N Engl J Med. 2021 Sep 23;385(13):1244-1246. doi: 10.1056/NEJMc2111462. Epub 2021 Aug 11.
6
Homing In On a SARS-CoV-2 Correlate of Protection.锁定新冠病毒的一种保护性相关因素
JAMA. 2022 Jan 11;327(2):115. doi: 10.1001/jama.2021.24117.
7
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
8
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.在先前感染过 SARS-CoV-2 的医护人员中，单次接种 ChAdOx1 nCoV-19 疫苗后的抗体反应。
EBioMedicine. 2021 Aug;70:103523. doi: 10.1016/j.ebiom.2021.103523. Epub 2021 Aug 12.
9
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.新型冠状病毒灭活疫苗在安全性和免疫原性方面的效果：两项随机临床试验的中期分析。
JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.
10
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.≥65 岁成年人中同时接种高剂量四价流感疫苗和 mRNA-1273 新冠疫苗第三针的安全性和免疫原性：一项 2 期、随机、开放标签研究。
Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1.

引用本文的文献

1
Lung-resident SARS-CoV-2 peptide-specific immune responses in perfused 3D human lung explant models.灌注3D人肺外植体模型中肺部驻留的SARS-CoV-2肽特异性免疫反应
Front Bioeng Biotechnol. 2025 Jul 8;13:1587080. doi: 10.3389/fbioe.2025.1587080. eCollection 2025.
2
Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines.葡萄牙医护人员在新冠疫情期间的纵向免疫学分析揭示了对疫苗体液免疫反应的差异。
Vaccines (Basel). 2024 Nov 30;12(12):1358. doi: 10.3390/vaccines12121358.
3
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.

本文引用的文献

1
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.抗 SARS-CoV-2 刺突 IgG 的一年耐久性：来自 anticrown 前瞻性观察研究的初步数据，研究 COVID-19 抗刺突 IgG 的一年耐久性。
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.023. Epub 2021 May 27.
2
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的B.1.1.7和B.1.351刺突变异体与人类血管紧张素转换酶2（ACE2）的结合亲和力增强。
Lancet Infect Dis. 2021 Aug;21(8):1070. doi: 10.1016/S1473-3099(21)00262-0. Epub 2021 May 19.
3
既往 COVID-19 免疫接种和/或既往感染对免疫应答和临床结局的影响。
Viruses. 2024 Apr 26;16(5):685. doi: 10.3390/v16050685.
4
Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.通过印度泰米尔纳德邦的两波 COVID 疫情，感染和疫苗接种对人群血清阳性率的贡献。
Sci Rep. 2024 Jan 24;14(1):2091. doi: 10.1038/s41598-023-50338-3.
5
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.新冠病毒感染和接种疫苗后的SARS-CoV-2抗体动态变化：一项真实世界横断面分析
Vaccines (Basel). 2023 Jun 30;11(7):1184. doi: 10.3390/vaccines11071184.
6
Paediatric healthcare and hospital worker SARS-CoV-2 IgG antibody: A longitudinal cohort study.儿科医护人员的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）IgG抗体：一项纵向队列研究。
IJID Reg. 2023 Jun;7:281-286. doi: 10.1016/j.ijregi.2023.05.001. Epub 2023 May 12.
7
Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study.mRNA-1273接种者中反应原性对抗SARS-CoV-2抗体反应的预测价值：一项多中心前瞻性队列研究
Vaccines (Basel). 2023 Jan 3;11(1):120. doi: 10.3390/vaccines11010120.
8
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.快速评估疫苗对 SARS-CoV-2 变异株的加强针效力。
Microbiol Spectr. 2022 Oct 26;10(5):e0225722. doi: 10.1128/spectrum.02257-22. Epub 2022 Sep 7.
9
Serological Response and Relationship with Gender-Sensitive Variables among Healthcare Workers after SARS-CoV-2 Vaccination.新冠病毒疫苗接种后医护人员的血清学反应及其与性别敏感变量的关系
J Pers Med. 2022 Jun 18;12(6):994. doi: 10.3390/jpm12060994.
10
Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers.mRNA新冠疫苗接种后的长期血清学SARS-CoV-2 IgG动力学：来自大量医护人员队列的真实世界数据
Int J Infect Dis. 2022 Sep;122:1-7. doi: 10.1016/j.ijid.2022.05.026. Epub 2022 May 11.
Waning antibodies to SARS-CoV-2 - Don't panic.
针对新冠病毒的抗体水平下降——别恐慌。
Lancet Reg Health Eur. 2021 May;4:100115. doi: 10.1016/j.lanepe.2021.100115. Epub 2021 May 5.
4
Vaccine Breakthrough Infections with SARS-CoV-2 Variants.疫苗突破感染 SARS-CoV-2 变异株。
N Engl J Med. 2021 Jun 10;384(23):2212-2218. doi: 10.1056/NEJMoa2105000. Epub 2021 Apr 21.
5
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.新冠病毒mRNA-1273疫苗第二剂接种后6个月的抗体持久性
N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.
6
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.mRNA-1273疫苗引发的血清中和活性。
N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.
7
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
8
Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody.用于特定 SARS-CoV-2 抗体的化学发光测定法的验证。
Clin Chem Lab Med. 2020 Jul 28;58(8):1357-1364. doi: 10.1515/cclm-2020-0594.